US Bancorp
DNLI icon

US Bancorp’s Denali Therapeutics DNLI Stock Holding History

US Bancorp’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4K Buy
950
+48
+5% +$986 ﹤0.01% 3116
2026
Q1 		$17.3K Buy
902
+68
+8% +$1.35K ﹤0.01% 3173
2025
Q4 		$13.8K Buy
834
+138
+20% +$2.33K ﹤0.01% 3221
2025
Q3 		$10.1K Buy
696
+255
+58% +$3.66K ﹤0.01% 3309
2025
Q2 		$6.17K Sell
441
-93
-17% -$1.31K ﹤0.01% 3573
2025
Q1 		$7.26K Sell
534
-479
-47% -$9.18K ﹤0.01% 3541
2024
Q4 		$20.6K Sell
1,013
-155
-13% -$3.97K ﹤0.01% 3141
2024
Q3 		$34K Sell
1,168
-448
-28% -$11.1K ﹤0.01% 2917
2024
Q2 		$37.5K Buy
1,616
+863
+115% +$16.6K ﹤0.01% 2807
2024
Q1 		$15.5K Buy
753
+254
+51% +$4.77K ﹤0.01% 3189
2023
Q4 		$10.7K Sell
499
-341
-41% -$6.75K ﹤0.01% 3301
2023
Q3 		$17.3K Buy
840
+255
+44% +$6.47K ﹤0.01% 2950
2023
Q2 		$17.3K Sell
585
-71
-11% -$2K ﹤0.01% 3047
2023
Q1 		$15.1K Buy
656
+199
+44% +$5.48K ﹤0.01% 3122
2022
Q4 		$12.7K Sell
457
-46
-9% -$1.37K ﹤0.01% 3217
2022
Q3 		$15K Buy
503
+46
+10% +$1.5K ﹤0.01% 3175
2022
Q2 		$13K Sell
457
-102
-18% -$2.67K ﹤0.01% 3265
2022
Q1 		$18K Buy
559
+115
+26% +$3.96K ﹤0.01% 3128
2021
Q4 		$20K Buy
444
+6
+1% +$284 ﹤0.01% 3107
2021
Q3 		$22K Sell
438
-40
-8% -$2.25K ﹤0.01% 3077
2021
Q2 		$37K Buy
478
+12
+3% +$742 ﹤0.01% 2813
2021
Q1 		$27K Buy
466
+71
+18% +$4.75K ﹤0.01% 2884
2020
Q4 		$33K Buy
395
+254
+180% +$15.4K ﹤0.01% 2681
2020
Q3 		$5K Buy
141
+57
+68% +$1.72K ﹤0.01% 3283
2020
Q2 		$2K Buy
+84
New +$1.98K ﹤0.01% 3492

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

US Bancorp's DNLI Position: Q2 2026 in Review

US Bancorp increased its Denali Therapeutics (DNLI) stake by 5.3% in Q2 2026, buying an estimated $986 and bringing the position to 950 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3116.

US Bancorp first reported a position in DNLI in Q2 2020 and has held it in 25 quarters since. The position peaked at $37.5K in Q2 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • US Bancorp held 950 shares of Denali Therapeutics worth $24.4K as of Q2 2026.
  • US Bancorp bought 48 Denali Therapeutics shares in Q2 2026, an estimated $986.
  • Denali Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3116 holding.
  • US Bancorp first reported a position in Denali Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • US Bancorp's Denali Therapeutics position peaked at $37.5K in Q2 2024.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.